Daily Filing Digest — Tuesday, 18 Aug 2026

1,451 filings screened from yesterday's Day Pack, 25 primary documents pulled and read, 134 evidence rows extracted — a heavy transcript day, with four items clearing the bar and one earning a full article.

Today's filings

• GRASIM (Grasim Industries) — Q1 FY27 call: Birla Opus CEO Himanshu Kapania, per the filed transcript, claims the paints venture has "emerged India's third largest decorative paints brand by revenue" two years after launch, alongside "the largest organized paint retail network in India" (qualified "as per our estimates"). Consolidated revenue ₹48,716 cr (+21% YoY). The claim reshapes the challenger ladder — full article today. (Filed transcript, 17-Aug-2026, p.3)
• SOMANYCERA (Somany Ceramics) — Q1 FY27 call: value growth ~24% on volume growth of only ~3%, driven by a 16–17% price hike; standalone EBITDA margin 8.0% → 11.6% on utilisation rising to 83%. Management on the Morbi cluster: "15% to 17% of Morbi, which has not started is never going to start." A capacity-exit claim worth tracking against future pricing. (Filed transcript, 17-Aug-2026, p.5)
• V2RETAIL (V2 Retail) — Q1 FY27 call: revenue +58% YoY to ₹997 cr, EBITDA +60%, PAT +70%; 56 net store additions in the quarter to 381 stores, crossing 400 subsequently. Value-retail distribution engine running hot. (Filed transcript, 17-Aug-2026)
• CAMLINFINE (Camlin Fine Sciences) — Q1 FY27 call: revenue +28% YoY but sharp EBITDA-margin compression, attributed by management to raw material and geopolitical pressure plus an ~₹8 cr negative in Brazil expected to correct in Q2. The gap between top-line growth and margin delivery goes to the watchlist. (Filed transcript, 17-Aug-2026, p.10)

From today's filings

The GRASIM transcript is the day's article: "Paint Wars: Birla Opus Claims Third Place" — the challenger's own words, read against the claims already on the record from JSW, Berger, and Asian Paints. Staged for Sunday's Weekly Filing Digest: Kapania's dealer-stocking caveat (THE FINE PRINT candidate — Q1 volumes flattered by dealers stocking ahead of an industry price increase, his own words), and Somany's Morbi capacity-exit claim (THE RECEIPTS candidate).

Educational research, not investment advice. No buy/sell recommendations, no price targets. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.